OptiMATe

Hematological neoplasms
Other indications (e.g. myeloproliferative diseases), Non-Hodgkin lymphoma
First-Line-Therapy (Metastatic Disease/Hematology)
To demonstrate the superiority of de-escalated induction therapy followed by autologous stem cell transplantation compared to the standard MATRix protocol in terms of event-free survival (EFS).
To demonstrate the superiority of de-escalated induction therapy followed by autologous stem cell transplantation compared to the standard MATRix protocol in terms of event-free survival (EFS).